Dustin J Maly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7225908/publications.pdf

Version: 2024-02-01

100	4,184	109321	133252
papers	citations	35 h-index	59 g-index

110	110	110	4775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allosteric Inhibition of the IRE1Î± RNase Preserves Cell Viability and Function during Endoplasmic Reticulum Stress. Cell, 2014, 158, 534-548.	28.9	384
2	Druggable sensors of the unfolded protein response. Nature Chemical Biology, 2014, 10, 892-901.	8.0	181
3	Divergent allosteric control of the IRE1Î± endoribonuclease using kinase inhibitors. Nature Chemical Biology, 2012, 8, 982-989.	8.0	175
4	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nature Structural and Molecular Biology, 2010, 17, 602-607.	8.2	172
5	Targeting ABL-IRE1Î± Signaling Spares ER-Stressed Pancreatic Î² Cells to Reverse Autoimmune Diabetes. Cell Metabolism, 2017, 25, 883-897.e8.	16.2	149
6	Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. Cancer Research, 2009, 69, 2384-2392.	0.9	134
7	Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii. ACS Medicinal Chemistry Letters, 2010, 1, 331-335.	2.8	126
8	Development of Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitors with Potent Anti-Toxoplasma Activity. Journal of Medicinal Chemistry, 2012, 55, 2416-2426.	6.4	101
9	Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. Journal of Clinical Investigation, 2012, 122, 2301-2305.	8.2	90
10	Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. Nature Methods, 2017, 14, 891-896.	19.0	88
11	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. Journal of Infectious Diseases, 2014, 209, 275-284.	4.0	83
12	Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. Journal of Medicinal Chemistry, 2016, 59, 6531-6546.	6.4	81
13	Sequence Determinants of a Specific Inactive Protein Kinase Conformation. Chemistry and Biology, 2013, 20, 806-815.	6.0	77
14	Structural and Functional Analysis of the Allosteric Inhibition of IRE1Î± with ATP-Competitive Ligands. ACS Chemical Biology, 2016, 11, 2195-2205.	3.4	75
15	In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. Antimicrobial Agents and Chemotherapy, 2015, 59, 6361-6374.	3.2	72
16	Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. Experimental Parasitology, 2017, 180, 71-83.	1.2	71
17	A Novel Calcium-Dependent Protein Kinase Inhibitor as a Lead Compound for Treating Cryptosporidiosis. Journal of Infectious Diseases, 2013, 208, 1342-1348.	4.0	67
18	Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3547-3549.	3.2	66

#	Article	IF	Citations
19	Neospora caninum Calcium-Dependent Protein Kinase 1 Is an Effective Drug Target for Neosporosis Therapy. PLoS ONE, 2014, 9, e92929.	2.5	63
20	Multiple Determinants for Selective Inhibition of Apicomplexan Calcium-Dependent Protein Kinase CDPK1. Journal of Medicinal Chemistry, 2012, 55, 2803-2810.	6.4	60
21	Multi-input chemical control of protein dimerization for programming graded cellular responses. Nature Biotechnology, 2019, 37, 1209-1216.	17.5	59
22	Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. European Journal of Medicinal Chemistry, 2014, 74, 562-573.	5.5	54
23	Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. Journal of Infectious Diseases, 2016, 214, 1856-1864.	4.0	54
24	Active site profiling reveals coupling between domains in SRC-family kinases. Nature Chemical Biology, 2013, 9, 43-50.	8.0	53
25	Bivalent inhibitors of protein kinases. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 102-115.	5.2	52
26	Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2334-2341.	3.0	52
27	Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Infectious Diseases, 2017, 215, 1275-1284.	4.0	52
28	Small molecule inhibition of IRE1Î± kinase/RNase has anti-fibrotic effects in the lung. PLoS ONE, 2019, 14, e0209824.	2.5	51
29	Potent and Selective Inhibitors of CDPK1 from T. gondii and C. parvum Based on a 5-Aminopyrazole-4-carboxamide Scaffold. ACS Medicinal Chemistry Letters, 2014, 5, 40-44.	2.8	49
30	Affinity-Based Probes Based on Type II Kinase Inhibitors. Journal of the American Chemical Society, 2012, 134, 19017-19025.	13.7	47
31	The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. Parasitology, 2014, 141, 1499-1509.	1.5	47
32	A Combined Approach Reveals a Regulatory Mechanism Coupling Srcâ€™s Kinase Activity, Localization, and Phosphotransferase-Independent Functions. Molecular Cell, 2019, 74, 393-408.e20.	9.7	45
33	Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. Journal of Infectious Diseases, 2017, 216, 55-63.	4.0	44
34	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. PLoS ONE, 2016, 11, e0149996.	2.5	44
35	Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. Nature Communications, 2020, 11, 2697.	12.8	42
36	In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites. International Journal for Parasitology, 2017, 47, 811-821.	3.1	40

#	Article	IF	Citations
37	Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G. MBio, 2016, 7, .	4.1	37
38	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. International Journal for Parasitology, 2020, 50, 413-422.	3.1	37
39	Affinity Reagents that Target a Specific Inactive Form of Protein Kinases. Chemistry and Biology, 2010, 17, 195-206.	6.0	36
40	Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors. Journal of Proteome Research, 2017, 16, 1216-1227.	3.7	36
41	A Chemical Genetic Method for Generating Bivalent Inhibitors of Protein Kinases. Journal of the American Chemical Society, 2009, 131, 6686-6688.	13.7	33
42	SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1. ACS Medicinal Chemistry Letters, 2015, 6, 1184-1189.	2.8	32
43	Intracellular Delivery of Bioactive Molecules using Light-Addressable Nanocapsules. ACS Nano, 2010, 4, 7603-7611.	14.6	31
44	Conformation-Selective Inhibitors Reveal Differences in the Activation and Phosphate-Binding Loops of the Tyrosine Kinases Abl and Src. ACS Chemical Biology, 2013, 8, 2734-2743.	3.4	30
45	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30
46	Conformation-Selective ATP-Competitive Inhibitors Control Regulatory Interactions and Noncatalytic Functions of Mitogen-Activated Protein Kinases. Chemistry and Biology, 2014, 21, 628-635.	6.0	29
47	Targeting Diverse Signaling Interaction Sites Allows the Rapid Generation of Bivalent Kinase Inhibitors. ACS Chemical Biology, 2012, 7, 487-495.	3.4	26
48	Parallel Signaling through IRE1Î± and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Research, 2019, 79, 6190-6203.	0.9	25
49	A Small Molecule-Regulated Guanine Nucleotide Exchange Factor. Journal of the American Chemical Society, 2010, 132, 938-940.	13.7	24
50	Divergent Modulation of Src-Family Kinase Regulatory Interactions with ATP-Competitive Inhibitors. ACS Chemical Biology, 2014, 9, 1894-1905.	3.4	24
51	Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
52	Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Systems, 2020, 11, 196-207.e7.	6.2	24
53	Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma. Molecular Cancer Therapeutics, 2015, 14, 419-428.	4.1	23
54	Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity. ACS Chemical Biology, 2016, 11, 121-131.	3.4	23

#	Article	IF	Citations
55	Subcellular drug targeting illuminates local kinase action. ELife, 2019, 8, .	6.0	23
56	Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. International Journal for Parasitology, 2016, 46, 871-880.	3.1	22
57	A computationally engineered RAS rheostat reveals RASâ€“ERK signaling dynamics. Nature Chemical Biology, 2017, 13, 119-126.	8.0	21
58	Rapid profiling of protein kinase inhibitors by quantitative proteomics. MedChemComm, 2014, 5, 363-369.	3.4	20
59	SH2-Catalytic Domain Linker Heterogeneity Influences Allosteric Coupling across the SFK Family. Biochemistry, 2014, 53, 6910-6923.	2.5	20
60	Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. ACS Chemical Biology, 2019, 14, 1249-1259.	3.4	20
61	Bumped kinase inhibitor prohibits egression in Babesia bovis. Veterinary Parasitology, 2016, 215, 22-28.	1.8	19
62	A Hexylchloride-Based Catch-and-Release System for Chemical Proteomic Applications. ACS Chemical Biology, 2013, 8, 691-699.	3.4	17
63	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
64	Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity. Combinatorial Chemistry and High Throughput Screening, 2007, 10, 652-666.	1.1	16
65	Development of a Chemical Toolset for Studying the Paralog-Specific Function of IRE1. ACS Chemical Biology, 2019, 14, 2595-2605.	3.4	16
66	A Chemically Disrupted Proximity System for Controlling Dynamic Cellular Processes. Journal of the American Chemical Society, 2019, 141, 3352-3355.	13.7	16
67	One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. Veterinary Parasitology, 2021, 289, 109336.	1.8	16
68	5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5487-5491.	2.2	15
69	How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. ACS Chemical Biology, 2020, 15, 2005-2016.	3.4	15
70	Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. Molecular Omics, 2018, 14, 26-36.	2.8	14
71	Rheostatic Control of Cas9-Mediated DNA Double Strand Break (DSB) Generation and Genome Editing. ACS Chemical Biology, 2018, 13, 438-442.	3.4	13
72	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. Journal of Infectious Diseases, 2019, 219, 1464-1473.	4.0	13

#	Article	IF	Citations
73	Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. Molecular BioSystems, 2011, 7, 447-456.	2.9	12
74	Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
75	Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 9-19.	3.4	12
76	Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. International Journal of Antimicrobial Agents, 2020, 56, 106099.	2.5	12
77	Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes. Journal of the American Chemical Society, 2019, 141, 11912-11922.	13.7	11
78	Design, synthesis and characterization of â€œclickableâ€•4-anilinoquinazoline kinase inhibitors. Molecular BioSystems, 2008, 4, 542.	2.9	10
79	Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors. Biochemistry, 2018, 57, 5897-5909.	2.5	9
80	P-Glycoproteinâ€“Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium. Journal of Infectious Diseases, 2019, 220, 1188-1198.	4.0	7
81	Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks. Journal of Proteome Research, 2020, 19, 1235-1247.	3.7	7
82	ATP-competitive partial antagonists of the IRE1Î± RNase segregate outputs of the UPR. Nature Chemical Biology, 2021, 17, 1148-1156.	8.0	7
83	Proteomic Profiling of Protein Kinase Inhibitor Targets by Mass Spectrometry. Methods in Molecular Biology, 2017, 1636, 105-117.	0.9	7
84	Label Transfer Reagents to Probe p38 MAPK Binding Partners. ChemBioChem, 2013, 14, 209-216.	2.6	6
85	Parallel Chemoselective Profiling for Mapping Protein Structure. Cell Chemical Biology, 2020, 27, 1084-1096.e4.	5.2	6
86	A novel protein kinase is essential in bloodstream Trypanosoma brucei. International Journal for Parasitology, 2016, 46, 479-483.	3.1	5
87	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. ACS Infectious Diseases, 2018, 4, 516-522.	3.8	5
88	â€œExamining RAS pathway rewiring with a chemically inducible activator of RASâ€• Small GTPases, 2020, 11, 413-420.	1.6	5
89	Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4951-4955.	2.2	3
90	In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. Veterinary Parasitology, 2018, 251, 90-94.	1.8	3

#	Article	IF	Citations
91	Temporal and rheostatic control of genome editing with a chemically-inducible Cas9. Methods in Enzymology, 2020, 633, 119-141.	1.0	3
92	Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. ACS Infectious Diseases, 2021, 7, 1200-1207.	3.8	3
93	Exploring the Intermembrane Space. ACS Chemical Biology, 2007, 2, 213-216.	3.4	2
94	The Right Tool for the Job: A Chemical and Genetic Toolkit for Interrogating DCLK1 Function. Cell Chemical Biology, 2020, 27, 1221-1223.	5.2	2
95	Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors. Methods in Molecular Biology, 2017, 1636, 79-89.	0.9	2
96	Protocol for rapidly inducible Cas9 and DSB-ddPCR. Protocol Exchange, 0, , .	0.3	2
97	Profiling the Dual Enzymatic Activities of the Serine/Threonine Kinase IRE1Î±. Methods in Molecular Biology, 2017, 1513, 233-242.	0.9	1
98	A chemically-controlled system for activating RAS GTPases. Methods in Enzymology, 2020, 633, 103-117.	1.0	0
99	Label Transfer Reagents for the Study of Protein Kinase Complexes. FASEB Journal, 2012, 26, 755.3.	0.5	0
100	Investigating inactive conformations of protein kinases. FASEB Journal, 2013, 27, 1042.1.	0.5	0